68 Ga Trivehexin PET/CT in a Breast Carcinoma Patient With Distant Metastasis : Edge Over 18 F-FDG PET/CT?
case_report · Level V
Where this comes from
- Record sourced from PubMed, PMID 41649854.
- Also identified by DOI 10.1097/RLU.0000000000006178.
- No licence information is recorded for this record.
- Because redistribution is not established, this page shows the abstract only. Follow the links below for the full text.
Abstract
FDG PET CT has limitations in breast cancer due to its low tracer uptake in Grade 1 and 2 tumors, estrogen receptor positivity, lobular histology, and osteoblastic skeletal metastases. Trivehexin PET targets αvβ6 integrin, which is relatively specific for epithelial cancer cells. We present a case of a 67-year-old woman with recently diagnosed metastatic breast cancer. Trivehexin PET not only showed lesions with a higher target-to-background ratio compared with FDG PET but also depicted additional metastatic sites.
Medical subject headings
- Positron Emission Tomography Computed Tomography
- Fluorodeoxyglucose F18
- Breast Neoplasms
- Gallium Radioisotopes